In the Claims:

Please add new claim 15.

15. (New Claim) A method of determining whether a canine is susceptible to canine malignant hyperthermia, comprising the step of obtaining a nucleic acid sample from a canine and examining the sample for the presence or absence of a nucleic acid encoding SEQ ID NO:1, wherein the presence of a nucleic acid encoding SEQ ID NO:1 indicates that the canine is susceptible to canine malignant hyperthermia.

1. (Original) A method of determining whether a canine is susceptible to canine malignant hyperthermia, comprising the step of obtaining a nucleic acid sample from a canine and examining the sample for the presence or absence of a T1640C mutation, wherein the presence of the mutation indicates that the canine is susceptible to canine malignant hyperthermia.

2. (Original) The method of claim 1 wherein the nucleic acid sample is a genomic DNA sample.

3. (Original) The method of claim 2 wherein the DNA is obtained from cheek cells.

4. (Original) The method of claim 2 wherein the DNA is obtained from muscle cells.

5. (Original) The method of claim 2 wherein the DNA is obtained from blood cells.

6. (Original) The method of claim 1 wherein the step of examining the sample for the presence or absence of a T1640C mutation comprises amplifying a portion of the canine RYR1 gene, wherein the portion comprises nucleotide 1640, and examining the amplified product for the presence of the T1640C mutation.

7. (Original) The method of claim 6 wherein the portion comprises the sequence between Exon 14 and Exon 16 of the RYRI gene.

8. (Original) The method of claim 6 further comprising the step of digesting the amplification product with a restriction endonuclease.

9. (Original) The method of claim 7 further comprising the step of digesting the amplified product with a restriction endonuclease.

10. (Original) The method of claim 8 wherein the restriction endonuclease is MscI.

11. (Original) The method of claim 9 wherein the restriction endonuclease is Mscl.

12. (Original) A kit for determining whether a canine is susceptible to canine malignant hyperthermia comprising:

(a) a set of primers useful for amplifying at least a portion of the RYRI gene, wherein the amplified portion comprises nucleotide 1640; and

(b) a restriction endonuclease capable of differential cleavage in the presence or absence of a T1640C mutation.

13. (Original) The kit of claim 12 wherein the restriction endonuclease is MscI.

14. (Original) The kit of claim 12 wherein the primers comprise SEQ ID NOs:19 and 20.

No fees are believed necessary to enter this amendment. However, if any fees are necessary please charge Deposit Account 17-0055.

Respectfully submitted,

Kirk J. Hogan, et al.

December 18, 2003 By: Jean C. Baker

Jean C. Baker
Reg. No. 35,433
Quarles & Brady LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202-4497
(414) 277-5709